FASEB J. Mp Biomedicals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
18/6/702
03-0562fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stolen, C. M.
Right arrow Articles by Jalkanen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stolen, C. M.
Right arrow Articles by Jalkanen, S.
The FASEB Journal Express Article doi:10.1096/fj.03-0562fje
Published online February 20, 2004

Semicarbazide-sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications

Craig M. Stolen, Rami Madanat, Luc Marti, Seppo Kari, Gennady G. Yegutkin, Hannu Sariola, Antonio Zorzano, and Sirpa Jalkanen

E-mail contact: craig.stolen{at}utu.fi

Semicarbazide-sensitive amine oxidases (SSAO) are copper-containing enzymes that oxidatively deaminate primary amines to produce hydrogen peroxide, ammonium, and specific aldehydes. Vascular adhesion protein-1 (VAP-1) is a cell surface and soluble molecule that possesses SSAO activity. VAP-1 protein, SSAO activity, and SSAO reaction products are elevated in the serum of patients with diabetes, congestive heart failure, and specific inflammatory liver diseases. By expressing human VAP-1/SSAO on mouse endothelial cells and subsequently in the serum, and by chronically treating the transgenic mice for 15 months with a high-fat diet and a physiological substrate for SSAO, methylamine, the in vivo roles of SSAO were assessed. The VAP-1 transgene increased the mouse body mass index and subcutaneous abdominal fat pad weights in a manner independent of food consumption. The transgene together with increased SSAO substrate availability enhanced glucose uptake in an SSAO-dependent manner. The increased SSAO activity also led to diabetes-like complications, including advanced glycation end product formation, elevated blood pressure, altered atherosclerosis progression, and nephropathy. These findings suggest that, although manipulation of VAP-1/SSAO has potential to serve as a therapeutic treatment in insulin-resistant conditions, care must be taken to fully understand its impact on obesity and vascular damage.

Key words: vascular adhesion protein-1 • amine oxidase (copper-containing) • transgene • obesity • vascular complications




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Jalkanen and M. Salmi
VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation
Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 18 - 26.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Jalkanen, M. Karikoski, N. Mercier, K. Koskinen, T. Henttinen, K. Elima, K. Salmivirta, and M. Salmi
The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding
Blood, September 15, 2007; 110(6): 1864 - 1870.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. Lautamaki, R. Borra, P. Iozzo, M. Komu, T. Lehtimaki, M. Salmi, S. Jalkanen, K. E. J. Airaksinen, J. Knuuti, R. Parkkola, et al.
Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E282 - E290.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
P. H. Yu, L.-X. Lu, H. Fan, M. Kazachkov, Z.-J. Jiang, S. Jalkanen, and C. Stolen
Involvement of Semicarbazide-Sensitive Amine Oxidase-Mediated Deamination in Lipopolysaccharide-Induced Pulmonary Inflammation
Am. J. Pathol., March 1, 2006; 168(3): 718 - 726.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. M. Salter-Cid, E. Wang, A. M. O'Rourke, A. Miller, H. Gao, L. Huang, A. Garcia, and M. D. Linnik
Anti-Inflammatory Effects of Inhibiting the Amine Oxidase Activity of Semicarbazide-Sensitive Amine Oxidase
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 553 - 562.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. M. Stolen, G. G. Yegutkin, R. Kurkijarvi, P. Bono, K. Alitalo, and S. Jalkanen
Origins of Serum Semicarbazide-Sensitive Amine Oxidase
Circ. Res., July 9, 2004; 95(1): 50 - 57.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by The Federation of American Societies for Experimental Biology.